This document presents the estimated incidence of bloodstream infections (BSI) with three key antibiotic-resistant bacteria, at country level in EU/EEA countries, using public data sources.
This issue of the CDTR covers the period 16-22 April 2023 and includes updates on influenza, avian influenza, Marburg virus disease, COVID-19 and poliomyelitis.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 9-15 April 2023 and includes updates on influenza, Marburg virus disease, COVID-19, MERS-CoV, Measles and diphtheria.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 2-8 April 2023 and includes updates on mpox, Group A streptococcal, Influenza A(H5N1) infection, and Marburg virus disease.
Marburg virus disease (MVD), formerly known as Marburg haemorrhagic fever, is a severe disease in humans caused by Marburg marburgvirus (MARV). Although MVD is uncommon, MARV has the potential to cause epidemics with significant case fatality rates.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 19-25 March 2023 and includes updates on Marburg virus disease, iatrogenic botulism, COVID-19, Influenza, Group A streptococcal infection, cholera, poliomyelitis, measles, and extensively drug-resistant Pseudomonas aeruginosa.
This report provides an overview of the main findings of the 2020–2021 harmonised AMR monitoring in Salmonella spp., Campylobacter jejuni and C. coli in humans and food-producing animals and relevant meat thereof.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 27 February - 5 March 2023 and includes updates on COVID-19, group A streptococcal infection, influenza and influenza A(H5N1) , Middle East respiratory syndrome coronavirus (MERS-CoV), Mpox, poliomyelitis, Marburg virus disease and the Earthquakes in Türkiye, Syria.
Immediate health needs following earthquakes in Türkiye and Syria are mostly related to trauma and the disruption of healthcare, however, infectious disease threats may be concerning in the following two to four weeks.